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Chronic Obstructive Pulmonary Disease (COPD)
Joseph Earich RN, BSN
Otterbein University, Westerville, Ohio
Why COPD?
As of 2021 the CDC reports more than
16 million Americans are diagnosed
with COPD and estimate millions more
are undiagnosed (Centers for Disease
Control and Prevention, 2021).
In 2019, Chronic obstructive
pulmonary disease (COPD) is the third
leading cause of death worldwide,
causing 3.23 million deaths (World
Health Organization 2022).
Nearly 90% of COPD deaths in those
under 70 years of age occur in lowand middle-income countries (World
Health Organization 2022).
Health care costs due to potentially
preventable hospitalizations due to
COPD exacerbations resulted in $7.27
billion spent in the United States in
2017 ("Aggregate costs of potentially
preventable adult inpatient stays by
condition U.S. 2017," 2020).

Clinical Manifestations
Signs and symptoms of COPD
(McCance et al., 2018):
•
Shortness of breath, dyspnea
on exertion (DOE)
•
Wheezing, increased sputum
production, cough
•
Hypoxemia with exercise or
everyday tasks requiring
supplemental oxygen
•
History of smoking
•
Barrel chest
•
Prolonged expiration, chronic
hypoventilation
•
Cyanosis, polycythemia, cor
pulmonale

PFT reveals airway obstruction
(decreased FEV1) (Soriano et al.,
2018).
By the time individual seeks medical
care due to symptoms, considerable
airway damage is already present
(McCance et al., 2018).

Topic: Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable
respiratory disease characterized airflow limitation that is not fully reversible and
typically progressive. It includes two phenotypes that overlap with each other: chronic
bronchitis and emphysema (McCance et al., 2018). Significant exposure to noxious
particles or gasses creates chronic inflammation causing airway and alveolar
abnormalities (Soriano et al., 2018).

Chronic Bronchitis
Chronic exposure to irritant engages inflammatory cells such as neutrophils,
macrophages, and lymphocytes. These inflammatory cells cause bronchial edema,
increase the number and size of mucosal and goblet cells in the airway,
hypertrophy with fibrosis, and narrowing of the airway. Ciliary function is
impaired causing inability to clear thick mucus. Frequent bacterial infections
occur from compromised defense mechanisms in the lung (McCance et al., 2018).
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Emphysema
Emphysema is the destruction of alveoli caused by an imbalance of proteases,
antiproteases, oxidative stress, and apoptosis of structural lung cells (McCance et
al., 2018). Like chronic bronchitis, inflammatory cells (TNF-α, IL-8, and
chemokines) are increased fostering the destruction of bronchi and alveoli (Wang
et al., 2018). This results in significantly reduced surface area for gas exchange,
ventilation-perfusion mismatch, and hypoxemia (McCance et al., 2018).

Asthma
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS) is a
presentation of clinical features from both diseases. Like COPD, Asthma is an
inflammatory disease causing bronchial hyperresponsiveness,
bronchoconstriction, and airway obstruction (McCance et al., 2018). Asthmatics
may clinically resemble patients with COPD with several similar, but different
underlying mechanisms (Hikichi, et al., 2018).

Significance of Pathophysiology
Irreversible, pathologic inflammatory modifications occur in large central airways,
small peripheral airways, and in the lung. Bronchial edema and increased goblet
cell activity considerably increases mucous production and its tenacity. This is
seen in combination with the destruction of alveoli and loss of elasticity in the
bronchial walls. Together these phenotypes cause airway obstruction, hypoxemia,
and increase susceptibility to infection (McCance et al., 2018).
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Diagram 2. Alveolar changes in COPD (McCance et al., 2018).

Implications for Nursing Care
•
•
•

Diagnosis
Based on history of symptoms,
physical exam, chest imaging,
pulmonary function tests (PFTS) and
blood gas (McCance et al., 2018).
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COPD is not reversible. Prevention is best treatment. Treatment is based on symptom
management (McCance et al., 2018).
Smoking cessation is paramount in the prevention of COPD and to slow down the
progression of the disease (Soriano et al., 2018).
Chest physical therapy including deep breathing, incentive spirometry, and postural
drainage. Teaching nutritional counseling, respiratory hygiene, recognize early signs of
infection, and pursed-lip breathing to relieve dyspnea (McCance et al., 2018).
COPD commonly presents alongside other comorbidities such as cardiovascular disease,
causing increased risk of exacerbation. Identification and treatment of cardiac comorbidity
in COPD patients can help positively affect prognosis (André et al., 2019).
COPD patient will commonly require non-invasive ventilation (NIV) with supplemental
oxygen. Standard of care for acute respiratory failure and hypoxemia (Viniol & Vogelmeier,
2018).

Conclusion
COPD is comprised of two phenotypes: emphysema and chronic bronchitis. Frequent
exposure to noxious irritants causes inflammation and progressive irreversible damage
in the airway and lung. Smoking is a major cause of COPD and cessation is key in
preventing progression. Treatment is based upon symptom management to reduce
incidence of exacerbation (McCance et al., 2018).
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Diagram 1. Pathophysiology behind the process of COPD (McCance et al., 2018).

Treatment
Prevention of Exacerbations
Smoking cessation: key to prevent further morbidity and mortality.
Cessation can slow decline in forced expiratory volume in 1 second
(FEV1) (Hikichi et al., 2018).
Pharmacotherapy: current data suggests bronchodilation with longacting antimuscarinic antagonists (LAMA) (e.g., tiotropium)
monotherapy has a greater effect on exacerbation over long-acting B2agonist (LABA) (e.g., salmeterol) monotherapy (Viniol & Vogelmeier,
2018).
Inhaled corticosteroids: long-term oral corticosteroids not
recommended. Long-term treatment with inhaled corticosteroids
(ICS) may be considered for patients with history of exacerbations
especially if patient has high blood eosinophil count with asthma and
COPD overlap (Viniol & Vogelmeier, 2018).
Combination therapy: significant decrease in incidence of
exacerbations by combining LAMA and LABA/ICA compared to using
one or the other. ICS should be saved for certain circumstances (Viniol
& Vogelmeier, 2018).
Phosphodiesterase-4 inhibitor: GOLD guidelines recommend PDE-4
inhibitors with very severe airflow limitation (Viniol & Vogelmeier,
2018).
Prophylactic antibiotics: macrolide antibiotics indicated for patients
with moderate to severe airflow obstruction. Antibiotic resistance
should be considered when using therapy (Viniol & Vogelmeier,
2018).
Mucolytics: many inflammatory cells involved in COPD causing
stimulation of mucus production from goblet and submucosal cells
(Wang et al., 2018). Mucolytics useful in patients with moderate to
severe airflow obstruction despite inhaled therapy (McCance et al.,
2018).
Monoclonal antibodies: patients with elevated eosinophil level using
mepolizumab has been associated with decreased incidence of
exacerbation, however, no formal data to currently recommend this
treatment (Viniol & Vogelmeier, 2018).
Other Preventative Recommendations
Physical activity and pulmonary rehabilitation: strongest predictor of
mortality in COPD patients is activity level. COPD patients with low
activity levels have a higher mortality risk (Viniol & Vogelmeier,
2018).
Education and self-management
Vaccination: current guidelines recommend receiving both influenza
and pneumococcal vaccinations with evidence showing reduced
incidence of exacerbation (Viniol & Vogelmeier, 2018).
Treatment of COPD Exacerbations
Noninvasive ventilation: supplemental oxygenation is first-line
intervention in COPD exacerbation. Standard of care in acute
respiratory failure (Viniol & Vogelmeier, 2018).
B-agonist and anticholinergics: initial exacerbation treatment includes
short acting B2-agonists and short-acting anticholinergics (Viniol &
Vogelmeier, 2018).
Corticosteroids: have been shown to improve lung function and
oxygenation, shorten recovery time and duration of hospitalizations.
Should use no longer than 5-day treatment (Viniol & Vogelmeier,
2018).
Antibiotics: a 5–7day course of antibiotics can be initiated according to
ERS/ATS guidelines if purulent sputum is expectorated. Procalcitonin
level may be checked as a general marker for antibiotic treatment
(Viniol & Vogelmeier, 2018).
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